Brief: Statera Biopharma Inc Announces Institutional Review Board Approves Study Of STAT-205 For Acute Covid-19
19/10/2021 12:41
Oct 19 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA, INC. ANNOUNCES INSTITUTIONAL REVIEW
BOARD
APPROVES STUDY OF STAT-205 FOR ACUTE COVID-19
* STATERA BIOPHARMA INC - RESEARCHERS AT LOMA LINDA
UNIVERSITY
HEALTH TO EVALUATE PHARMACOKINETICS, BIOMARKERS AND SAFETY OF
STAT-205
* STATERA BIOPHARMA INC - A PHASE 2 STUDY IN POST-ACUTE
COVID-19
PATIENTS IS EXPECTED TO COMMENCE BY YEAR-END 2021
Source text for Eikon: ID:nGNX5fNwbN
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc